Based on current evidence, the IL-23 p19 inhibitors could be considered in a stratified treatment model, which could serve as the first-line options for biologic-naïve patients with high infection risk or comorbidities, alongside the second-line agents for those with anti-TNF failure. This evidence concerns the gene TNF and infection.